University Of Notre Dame Du Lac Mirati Therapeutics, Inc. Transaction History

University Of Notre Dame Du Lac

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $857,855 - $1.43 Million	-11,913 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $184,917 - $307,956	2,650 Added 28.61%	11,913 $916,000
Q4 2019 Feb 14, 2020	SELL	$70.76 - $128.86 $43,517 - $79,248	-615 Reduced 6.23%	9,263 $1.19 Million
Q3 2019 Nov 13, 2019	SELL	$77.91 - $109.6 $3.32 Million - $4.67 Million	-42,597 Reduced 81.18%	9,878 $770,000
Q2 2019 Aug 14, 2019	BUY	$59.49 - $104.71 $3.12 Million - $5.49 Million	52,475 New	52,475 $5.41 Million
Q4 2018 Feb 13, 2019	SELL	$32.0 - $47.43 $1.52 Million - $2.26 Million	-47,630 Closed	0 $0
Q3 2018 Nov 13, 2018	BUY	$47.1 - $62.7 $2.24 Million - $2.99 Million	47,630 New	47,630 $2.24 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of University Of Notre Dame Du Lac, based on Form 13F filings with the SEC.

Stay updated on University Of Notre Dame Du Lac with notifications on news.